IL33 and lung carcinoma: LL-37 cooperated with IL-33 to increase the phosphorylation of p38 MAPK as well as NF-κB p65 pathways, and augmented IL-6 and IL-1β secretion, thus resulting in the proliferation of lung cancer cells in vitro.